Immunologic biomarkers for clinical and therapeutic management of psoriasis

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Cordiali Fei, P ^a   Bianchi, L ^b   Bonifati, C ^a   Trento, E ^a   Ruzzetti, M ^b   Francesconi, F ^a   Bultrini, S ^a   D'Agosto, G ^a   Bordignon, V ^a   Francavilla, V ^a   Tripiciano, A ^a   Chiricozzi, A ^b   Campione, E ^b   Cavallotti, C ^a   Orlandi, A ^b   Berardesca, E ^a   Di Carlo, A ^a   Chimenti, S ^b   Ensoli, F ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN G; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; INTERLEUKINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927172500     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/236060     Document Type: Review

References (58)

1. A. S. Raut, R. H. Prabhu, and V. B. Patravale, "Psoriasis clinical implications and treatment: a review, " Critical Reviews inTherapeutic Drug Carrier Systems, vol. 30, no. 3, pp. 183-216, 2013.
2. J. T. Elder, "Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis, " Genes and Immunity, vol. 10, no. 3, pp. 201-209, 2009.
3. A. Morris, M. Rogers, G. Fischer, and K. Williams, "Childhood psoriasis: a clinical review of 1262 cases, " Pediatric Dermatology, vol. 18, no. 3, pp. 188-198, 2001.
4. L. Naldi, L. Peli, F. Parazzini, and C. F. Carrel, "Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study, " Journal of the American Academy of Dermatology, vol. 44, no. 3, pp. 433-438, 2001.
5. C. E. Griffiths and J. N. Barker, "Pathogenesis and clinical features of psoriasis, "The Lancet, vol. 370, no. 9583, pp. 263-271, 2007.
6. V. Chandran, "The genetics of psoriasis and psoriatic arthritis, " Clinical Reviews in Allergy and Immunology, vol. 44, no. 2, pp. 149-156, 2013.
7. W. R. Swindell, A. Johnston, J. J. Voorhees, J. T. Elder, and J. E. Gudjonsson, "Dissecting the psoriasis transcriptome: inflammatory-and cytokine-driven gene expression in lesions from163 patients, "BMCGenomics, vol. 14, no. 1, article 527, 2013.
8. J. P. McFadden, B. S. Baker, A. V. Powles, and L. Fry, "Psoriasis and streptococci: the natural selection of psoriasis revisited, " British Journal of Dermatology, vol. 160, no. 5, pp. 929-937, 2009.
9. L. C. Zaba, J. Fuentes-Duculan, N. J. Eungdamrong et al. , "Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells, " The Journal of Investigative Dermatology, vol. 129, no. 1, pp. 79-88, 2009.
10. K. E. Nograles, L. C. Zaba, E. Guttman-Yassky et al. , "Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways, " British Journal of Dermatology, vol. 159, no. 5, pp. 1092-1102, 2008.
11. M. S. Day, D. Nam, S. Goodman, E. P. Su, and M. Figgie, "Psoriatic arthritis, " Journal of the American Academy of Orthopaedic Surgeons, vol. 20, no. 1, pp. 28-37, 2012.
12. H. Rahimi and C. T. Ritchlin, "Altered bone biology in psoriatic arthritis, " Current Rheumatology Reports, vol. 14, no. 4, pp. 349-357, 2012.
13. M. L. McCully, K. Ladell, S. Hakobyan, R. E. Mansel, D. A. Price, and B. Moser, "Epidermis instructs skin homing receptor expression in human T cells, " Blood, vol. 120, no. 23, pp. 4591-4598, 2012.
14. R. C. Fuhlbrigge, J. D. Kieffer, D. Armerding, and T. S. Kupper, "Cutaneous lymphocyte antigen is a specialized formof PSGL-1 expressed on skin-homing T cells, " Nature, vol. 389, no. 6654, pp. 978-981, 1997.
15. S. Davison, A. Ballsdon, M. H. Allen, and J. N. W. N. Barker, "Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques, " Experimental Dermatology, vol. 10, no. 4, pp. 280-285, 2001.
16. H. Sigmundsdottir, J. E. Gudjonsson, I. Jonsdottir, B. R. Ludviksson, and H. Valdimarsson, "The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease, " Clinical and Experimental Immunology, vol. 126, no. 2, pp. 365-369, 2001.
17. M. Apostolaki, M. Armaka, P. Victoratos, and G. Kollias, "Cellular mechanisms of TNF function in models of inflammation and autoimmunity, " CurrentDirections in Autoimmunity, vol. 11, pp. 1-26, 2010.
18. J. G. Krueger, "The immunologic basis for the treatment of psoriasis with new biologic agents, " Journal of the American Academy of Dermatology, vol. 46, no. 1, pp. 1-26, 2002.
19. M. A. Palladino, F. R. Bahjat, E. A. Theodorakis, and L. L. Moldawer, "Anti-TNF-α therapies:Thenext generation, " Nature Reviews Drug Discovery, vol. 2, no. 9, pp. 736-746, 2003.
20. A. B. Gottlieb, F. Chamian, S. Masud et al. , "TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques, "TheJournal of Immunology, vol. 175, no. 4, pp. 2721-2729, 2005.
21. J. S. Gall and R. E. Kalb, "Infl iximab for the treatment of plaque psoriasis, " Biologics: Targets and Therapy, vol. 2, no. 1, pp. 115-124, 2008.
22. L. C. Zaba, I. Cardinale, P. Gilleaudeau et al. , "Amelioration of epidermal hyperplasia by TNF inhibition is associated with reducedTh17 response, "The Journal of Experimental Medicine, vol. 205, pp. 1517-1522, 2008.
23. M. A. Lowes, T. Kikuchi, J. Fuentes-Duculan et al. , "Psoriasis vulgaris lesions contain discrete populations ofTh1 andTh17 T cells, " Journal of Investigative Dermatology, vol. 128, no. 5, pp. 1207-1211, 2008.
24. E. Fitch, E. Harper, I. Skorcheva, S. E. Kurtz, and A. Blauvelt, "Pathophysiology of psoriasis: recent advances on IL-23 and TH17 cytokines, " Current Rheumatology Reports, vol. 9, no. 6, pp. 461-467, 2007.
25. H. L. Ma, S. Liang, J. Li et al. , "IL-22 is required for Th17 cellmediated pathology in a mouse model of psoriasis-like skin inflammation, " Journal of Clinical Investigation, vol. 118, no. 2, pp. 597-607, 2008.
26. K. Wolk, E. Witte, E. Wallace et al. , "IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis, " European Journal of Immunology, vol. 36, no. 5, pp. 1309-1323, 2006.
27. N. J. Wilson, K. Boniface, J. R. Chan et al. , "Development, cytokine profile and function of human interleukin 17-producing helper T cells, " Nature Immunology, vol. 8, no. 9, pp. 950-957, 2007.
28. H. Sugiyama, R. Gyulai, E. Toichi et al. , "Dysfunctional blood and target tissueCD4+CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation, " Journal of Immunology, vol. 174, no. 1, pp. 164-173, 2005.
29. W. A. Goodman, A. B. Young, T. S. McCormick, K. D. Cooper, and A. D. Levine, "Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression, " The Journal of Immunology, vol. 186, no. 6, pp. 3336-3345, 2011.
30. C. H. Smith, A. V. Anstey, J. N. W. N. Barker et al. , "BritishAssociation of Dermatologists guidelines for biologic interventions for psoriasis 2009, " British Journal of Dermatology, vol. 161, no. 5, pp. 987-1019, 2009.
31. C. E. M. Griffiths, B. E. Strober, P. van de Kerkhof et al. , "Comparison of ustekinumab and etanercept for moderate-tosevere psoriasis, "The New England Journal ofMedicine, vol. 362, no. 2, pp. 118-128, 2010.
32. S. Au, A. Madani, M. Alhaddad, M. Alkofide, and A. B. Gottlieb, "Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center, " Journal of Drugs in Dermatology, vol. 12, no. 8, pp. 861-866, 2013.
33. S. Piaserico, S. Cazzaniga, S. Chimenti et al. , "Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare Registry, " Journal of the American Academy of Dermatology, vol. 70, pp. 257-262, 2014.
34. W. Taylor, D. Gladman, P. Helliwell, A. Marchesoni, P. Mease, and H. Mielants, "Classification criteria for psoriatic arthritis: development of new criteria from a large international study, " Arthritis and Rheumatism, vol. 54, no. 8, pp. 2665-2673, 2006.
35. D. Pathirana, A. D. Ormerod, and P. Saiag, "European S3-Guidelines on the systemic treatment of psoriasis vulgaris, " Journal of the European Academy of Dermatology and Venereology, vol. 23, supplement 2, pp. 1-70, 2009.
36. L. Naldi, A. Addis, C. Tomino et al. , "Trattamento della psoriasi con farmaci sistemici in Italia, " http://www. agenziafarmaco . gov. it/it/content/registri-farmaci-sottoposti-monitoraggio.
37. C. R. Parish and H. S. Warren, "Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation, " Current Protocols in Immunology, Chapter4, Unit 4. 9, 2002.
38. P. Cordiali-Fei, M. Ardigo, A. Mastroianni et al. , "Serum cytokines and bioumoral immunological characterization of psoriatic patients in long term etanercept treatment, " International Journal of Immunopathology and Pharmacology, vol. 21, no. 3, pp. 643-649, 2008.
39. F. Wang, N. Smith, L. Maier et al. , "Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24, " British Journal of Dermatology, vol. 167, no. 1, pp. 92-102, 2012.
40. P. Quaglino, M. Bergallo, R. Ponti et al. , "Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response, " Dermatology, vol. 223, no. 1, pp. 57-67, 2011.
41. V. Chandran, H. Shen, R. A. Pollock et al. , "Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis, " Journal of Rheumatology, vol. 40, no. 6, pp. 866-871, 2013.
42. C. Larsen, A. Anderson, J. Oppenheim, and K. Matsushima, "Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumour necrosis factor, " Immunology, vol. 68, no. 1, pp. 31-36, 1989.
43. S. L. Kunkel, R. M. Strieter, S. W. Chensue et al. , "Tumornecrosis factor-alpha, interleukin-8 and chemotactic cytokines, " Progress in Clinical and Biological Research, vol. 349, pp. 433-444, 1990.
44. A. Li, S. Dubey, M. L. Varney, B. J. Dave, and R. K. Singh, "IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis, " Journal of Immunology, vol. 170, no. 6, pp. 3369-3376, 2003.
45. A. Michalak-Stoma, J. Bartosinska, M. Kowal, M. Juszkiewicz-Borowiec, A. Gerkowicz, and G. Chodorowska, "Serumlevels of selected Th17 and Th22 cytokines in psoriatic patients, " Disease Markers, vol. 35, pp. 625-631, 2013.
46. K. E. Nograles, B. Davidovici, and J. G. Krueger, "New insights in the immunologic basis of psoriasis, " Seminars in Cutaneous Medicine and Surgery, vol. 29, no. 1, pp. 3-9, 2010.
47. S. Rutz, C. Eidenschenk, and W. Ouyang, "IL-22, not simply a Th17 cytokine, " Immunological Reviews, vol. 252, no. 1, pp. 116-132, 2013.
48. P. C. M. Res, G. Piskin, O. J. de Boer et al. , "Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the pathogenesis of psoriasis, " PLoS ONE, vol. 5, no. 11, Article ID e14108, 2010.
49. W. A. Goodman, A. D. Levine, J. V. Massari, H. Sugiyama, T. S. McCormick, and K. D. Cooper, "IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells, "TheJournal of Immunology, vol. 183, no. 5, pp. 3170-3176, 2009.
50. W. A. Goodman, A. B. Young, T. S. McCormick, K. D. Cooper, and A. D. Levine, "Stat3 phosphorylationmediates resistance of primary human T cells to regulatory T cell suppression, " Journal of Immunology, vol. 186, no. 6, pp. 3336-3345, 2011.
51. M. Ferran, A. B. Galvan, C. Rincon et al. , "Streptococcus induces circulating CLA+ memory T-cell-dependent epidermal cell activation in psoriasis, " Journal of InvestigativeDermatology, vol. 133, no. 4, pp. 999-1007, 2013.
52. M. B. Teunissen, N. G. Yeremenko, D. L. Baeten et al. , "The IL-17A-producing CD8+ T cell population in psoriatic lesional skin comprises mucosa.-associated invariant T cells and conventional T cells, " Journal of Investigative Dermatology, 2014.
53. P. Quaglino, M. Ortoncelli, A. Comessatti et al. , "Circulating CD4+CD25 bright FOXP3+ T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients, " Dermatology, vol. 219, no. 3, pp. 250-258, 2009.
54. A. G. Richetta, C. Mattozzi, M. Salvi et al. , "CD4+ CD25+ Tregulatory cells in psoriasis. Correlation between their numbers and biologics-induced clinical improvement, " European Journal of Dermatology, vol. 21, no. 3, pp. 344-348, 2011.
55. K. S. Campbell and J. Hasegawa, "Natural killer cell biology: an update and future directions, " Journal of Allergy and Clinical Immunology, vol. 132, no. 3, pp. 536-544, 2013.
56. C. Ottaviani, F. Nasorri, C. Bedini, O. de Pita, G. Girolomoni, and A. Cavani, "CD56 bright CD16- NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation, " European Journal of Immunology, vol. 36, no. 1, pp. 118-128, 2006.
57. S. Dunphy and C. M. Gardiner, "NK cells and psoriasis, " Journal of Biomedicine and Biotechnology, vol. 2011, Article ID248317, 10 pages, 2011.
58. T. Cobo-Ibanez, M. A. Descalzo, E. Loza-Santamaria, L. Carmona, and S. Munoz-Fernandez, "Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2. 0, " Rheumatology International, vol. 34, no. 7, pp. 953-961, 2014.